NCT02102750View on ClinicalTrials.gov

A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

May 29, 2017

Study Completion Date

July 3, 2017

Conditions

GlaucomaOcular Hypertension

Interventions

DRUG

Preservative free tafluprost opthalmic solution

0.0015% eye drops q.d, in both eyes for 7 to 9 days

Trial Locations (2)

19104

Childrens Hospital of Philadelphia (CHOP), Philadelphia

EC1V 2PD

Moorfields Eye Hospital, London

All Listed Sponsors

lead

Santen Oy

INDUSTRY

NCT02102750 - A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter